TY - JOUR T1 - Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia JF - Anticancer Research JO - Anticancer Res SP - 6355 LP - 6364 VL - 35 IS - 12 AU - JAVIER PINILLA-IBARZ AU - KENDRA SWEET AU - JOSEPHINE EMOLE AU - MICHAEL FRADLEY Y1 - 2015/12/01 UR - http://ar.iiarjournals.org/content/35/12/6355.abstract N2 - With the success of tyrosine kinase inhibitor (TKI) therapy for the treatment of patients with chronic myeloid leukemia (CML), CML is now treated as a chronic disease. As such, the community of oncologists may see patients with CML more often than the primary-care physician and must focus on long-term management of adverse events and adherence. BCR-ABL1 TKIs are effective therapies in CML but are associated with distinct safety profiles. Thus, selection of long-term treatment with any TKI requires assessment of patient comorbidities and regular monitoring to identify the potential emergence of adverse effects or new risk factors. With a focus on long-term safety, this review provides a holistic picture of the primary care needs of patients with CML, emphasizing on the importance of community oncologists who in many cases act as both oncologists and primary-care physicians. ER -